{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:08:46Z","timestamp":1793657326727,"version":"4.5.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"Importance<\/jats:title>Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus<\/jats:italic> bacteremia without requiring long-term intravenous access.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the efficacy and safety of dalbavancin vs standard therapy for completion of treatment of complicated S aureus<\/jats:italic> bacteremia.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Open-label, assessor-masked, randomized clinical trial conducted from April 2021 to December 2023 at 23 medical centers in the US (n\u2009=\u200922) and Canada (n\u2009=\u20091). Participant follow-up lasted 70 days (180 days for participants with osteomyelitis); date of final follow-up was December 1, 2023. Hospitalized adults with complicated S aureus<\/jats:italic> bacteremia who achieved blood culture clearance following at least 72 hours but no more than 10 days of initial antibacterial therapy were included. Participants were excluded if they had central nervous system infection, retained infected prosthetic material, left-sided endocarditis, or severe immune compromise.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were randomly assigned to receive either 2 doses of intravenous dalbavancin (n\u2009=\u2009100; 1500 mg on days 1 and 8) or 4 to 8 total weeks of standard intravenous therapy (n\u2009=\u2009100; cefazolin or antistaphylococcal penicillin if methicillin susceptible; vancomycin or daptomycin if methicillin resistant).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the desirability of outcome ranking (DOOR) at day 70, which involved 5 components (clinical success, infectious complications, safety complications, mortality, and health-related quality of life) and was assessed for superiority (achieved if the 95% CI for the probability of dalbavancin having a superior DOOR was &amp;gt;50%). Secondary outcomes included clinical efficacy at day 70 (prespecified noninferiority margin of 20%) and safety.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 200 participants randomized (mean [SD] age, 56 [16.2] years; 62 females [31%]), 167 (84%) survived to day 70 and had an efficacy assessment. Participants without a day 70 efficacy assessment were treated as clinical failures in the analyses. The probability of a more desirable day 70 outcome with dalbavancin vs standard therapy was 47.7% (95% CI, 39.8% to 55.7%). Regarding secondary outcomes, clinical efficacy was documented in 73 of 100 for dalbavancin and 72 of 100 for standard therapy (difference, 1.0% [95% CI, \u221211.5% to 13.5%]), meeting the noninferiority criterion. Serious adverse events were reported in 40 of 100 participants who received dalbavancin and 34 of 100 participants who received standard therapy; treatment-related adverse events were uncommon in both groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Among adult participants with complicated S aureus<\/jats:italic> bacteremia who achieved blood culture clearance, dalbavancin was not superior to standard therapy by desirability of outcome ranking. When considered with other efficacy and safety outcomes these findings may help inform use of dalbavancin in clinical practice.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04775953<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2025.12543","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:00:22Z","timestamp":1755097222000},"page":"866","source":"Crossref","is-referenced-by-count":60,"title":["Dalbavancin for Treatment of Staphylococcus aureus<\/i> Bacteremia"],"prefix":"10.1001","volume":"334","author":[{"given":"Nicholas A.","family":"Turner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[{"name":"The Biostatistics Center and the Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Doernberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"},{"name":"Health Systems Research, Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, North Carolina"},{"name":"Division of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varduhi","family":"Ghazaryan","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Denver Health and University of Colorado, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Division of Allergy and Infectious Diseases, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrabani","family":"Sharma","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Zaharoff","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Wahid","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Duke University Health System, Durham, North Carolina"},{"name":"Department of Medicine, Virginia Tech Carilion School of Medicine, Roanoke"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie J.","family":"Renard","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Duke University Health System, Durham, North Carolina"},{"name":"Department of Medicine, Virginia Tech Carilion School of Medicine, Roanoke"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brody School of Medicine at East Carolina, Greenville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Raad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Hachem","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Chaftari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sims","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and International Medicine, Department of Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"DeMarco","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and International Medicine, Department of Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center and Lundquist Institute at Harbor-UCLA, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn G.","family":"Morse","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Lucasti","sequence":"additional","affiliation":[{"name":"South Jersey Infectious Disease, Somers Point, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme N.","family":"Forrest","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartikeya","family":"Cherabuddi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Florida, Gainesville"},{"name":"Division of Infectious Disease and International Medicine, University of South Florida and Tampa General Hospital, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Polk","sequence":"additional","affiliation":[{"name":"Atrium Health, Wake Forest School of Medicine, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasaduq","family":"Fazili","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Virginia Tech Carilion School of Medicine, Roanoke"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Rupp","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, UC-Davis Medical Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease and International Medicine, University of South Florida and Tampa General Hospital, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Strnad","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Schnee","sequence":"additional","affiliation":[{"name":"University of South Carolina School of Medicine, Greenville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"McKinnell","sequence":"additional","affiliation":[{"name":"Torrance Memorial Medical Center, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda P.","family":"Silveira","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pittsburgh and UPMC, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd P.","family":"McCarty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Paolino","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, SUNY Upstate Medical University, Syracuse, New York"},{"name":"Department of Medicine, SUNY Upstate Medical University, Syracuse, New York"},{"name":"Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Wiegand","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Wall","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[{"name":"AbbVie, Florham Park, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinal","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie, Florham Park, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urania","family":"Rappo","sequence":"additional","affiliation":[{"name":"BiomX Inc, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Evans","sequence":"additional","affiliation":[{"name":"The Biostatistics Center and the Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Holland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Antibacterial Resistance Leadership Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Evans","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Cross","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Harris","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda M.","family":"Pettigrew","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen W.","family":"Boucher","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Huntley","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanling","family":"Zou","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Raterman","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamika","family":"Samuel","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung","family":"Moon","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Hanson","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Holland","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lodise","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Shelburne","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Banerjee","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebbing","family":"Lautenbach","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Mehigan","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Doernberg","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Perdue","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Beigel","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Roach","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara A.","family":"Singh","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy A.","family":"Wickward","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Souto","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Waller","sequence":"additional","affiliation":[{"name":"for the Antibacterial Resistance Leadership Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10369","key":"joi250052r1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"400","author":"GBD 2019 Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"joi250052r2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review.","author":"Tong","journal-title":"JAMA"},{"issue":"15","key":"joi250052r3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia.","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"joi250052r4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"joi250052r5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cid\/cix733","article-title":"Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy.","volume":"66","author":"Keller","year":"2018","journal-title":"Clin Infect Dis"},{"key":"joi250052r6","doi-asserted-by":"publisher","DOI":"10.1177\/20499361231179668","article-title":"Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohort.","volume":"10","author":"Billmeyer","year":"2023","journal-title":"Ther Adv Infect Dis"},{"issue":"11","key":"joi250052r7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab486","article-title":"Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review.","volume":"8","author":"Cooper","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"joi250052r8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis.","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"23","key":"joi250052r9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection.","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"joi250052r10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection.","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"joi250052r11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"joi250052r12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"10","key":"joi250052r13","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"7","key":"joi250052r14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac335","article-title":"Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections.","volume":"9","author":"Molina","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"joi250052r15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population.","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"joi250052r16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci.","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"joi250052r17","doi-asserted-by":"publisher","first-page":"e2511641","DOI":"10.1001\/jamanetworkopen.2025.11641","article-title":"Comparative effectiveness of long-acting lipoglycopeptides vs standard-of-care antibiotics in serious bacterial infections.","volume":"8","author":"Goodman-Meza","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"joi250052r18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin nonsusceptible staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization.","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"joi250052r19","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"joi250052r20","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"joi250052r21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"issue":"22","key":"joi250052r22","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"joi250052r23","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"joi250052r24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02397-17","article-title":"Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and\/or linezolid from US medical centers.","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"joi250052r25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/pathogens13010088","article-title":"Antibiotic resistance to molecules commonly prescribed for the treatment of antibiotic-resistant gram-positive pathogens: what is relevant for the clinician?","volume":"13","author":"Tebano","year":"2024","journal-title":"Pathogens"},{"issue":"2","key":"joi250052r26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/cid\/ciaa611","article-title":"Patients\u2019 experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: a qualitative descriptive study and concept elicitation phase to inform measurement of patient-reported quality of life.","volume":"73","author":"King","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"joi250052r27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection.","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"joi250052r28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab622","article-title":"Patients\u2019 experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: results from cognitive interviews to inform assessment of health-related quality of life.","volume":"9","author":"King","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"joi250052r29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"joi250052r30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jmii.2017.08.002","article-title":"Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis, 12-year experience from a tertiary hospital in central Taiwan.","volume":"51","author":"Chang","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"joi250052r31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/cid\/ciw098","article-title":"Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence.","volume":"62","author":"Park","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"joi250052r32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2307\/2531493","article-title":"Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring.","volume":"45","author":"Halperin","year":"1989","journal-title":"Biometrics"},{"issue":"9","key":"joi250052r33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"joi250052r34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1177\/0272989X221099493","article-title":"Noninferiority margin size and acceptance of trial results: contingent valuation survey of clinician preferences for noninferior mortality.","volume":"42","author":"Pong","year":"2022","journal-title":"Med Decis Making"},{"issue":"6","key":"joi250052r35","doi-asserted-by":"publisher","first-page":"e2417199","DOI":"10.1001\/jamanetworkopen.2024.17199","article-title":"Antimicrobial resistance patterns of outpatient Staphylococcus aureus isolates.","volume":"7","author":"Carrel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"joi250052r36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates.","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"1","key":"joi250052r37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40121-021-00402-0","article-title":"Safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSI): nephrotoxicity rates compared with vancomycin: a post hoc analysis of three clinical trials.","volume":"10","author":"Gonzalez","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"5","key":"joi250052r38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis.","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"joi250052r39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection.","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"joi250052r40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/cid\/ciad666","article-title":"Early oral antibiotic switch in Staphylococcus aureus bacteraemia: the Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.","volume":"79","author":"de Kretser","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"9","key":"joi250052r41","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1007\/s11136-022-03126-x","article-title":"Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial.","volume":"31","author":"Bundgaard","year":"2022","journal-title":"Qual Life Res"},{"issue":"2","key":"joi250052r42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1128\/JCM.44.2.595-597.2006","article-title":"Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.","volume":"44","author":"Marty","year":"2006","journal-title":"J Clin Microbiol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2837604\/jama_turner_2025_oi_250052_1756415903.04421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:00:36Z","timestamp":1757430036000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2837604"}},"subtitle":["The DOTS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.12543","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}